Dr. Kundranda on the Need for Novel Treatments in Pancreatic Ductal Adenocarcinoma

Madappa Kundranda, MD, PhD, discusses the need ​to develop novel treatments in pancreatic ductal adenocarcinoma.

Madappa Kundranda, MD, PhD, director, Gastrointestinal Oncology Program, deputy chief, Division of Medical Oncology, Banner MD Anderson Cancer Center, discusses the need ​to develop novel treatments in pancreatic ductal adenocarcinoma (PDAC). 

​The current standards of care in PDAC are not sufficient, says Kundranda. As such, patients ​with PDAC, particularly those with a good performance status, should have the opportunity to participate in clinical trial​s.

​There are several ongoing trials ​in the pancreatic cancer paradigm, ​including the phase 3 NAPOLI-1 and AVENGER 500 studies, Kundranda explains. 

Furthermore, ​data evaluating the utility of ​neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel ​(Abraxane) in patients with resectable or borderline resectable pancreatic cancer were presented at the 2020 ASCO Virtual Scientific Program.

Ultimately, these data suggest that a triplet regimen might not be superior to a doublet, Kundranda concludes.